SARS_CoV_2 mutation literature information.


  Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study.
 PMID: 35305699       2022       The Lancet. Infectious diseases
Introduction: Deep mutational scanning data suggest that E484A and K417N, in addition to G446S and Q493R (which are not present in other variants of concern) are the largest contributors to the resistance profile of the omicron variant.


  A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations.
 PMID: 35222380       2022       Frontiers in immunology
Method: Many other mutations have been found in the Omicron variant, such as Q493R, G496S, Q498R in RBD and throughout the S-glycoprotein.


  SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week interval between doses.
 PMID: 35216664       2022       Cell reports
Method: We therefore generated and used an Omicron Spike bearing the Q493R mutation for the full manuscript (Figures 1 and 2 and Figure S1).
Discussion: As i
Discussion: Of note, the sequence initially released for the Omicron Spike contained the Q493K substitution, but was then corrected to Q493R.


  Allosteric Determinants of the SARS-CoV-2 Spike Protein Binding with Nanobodies: Examining Mechanisms of Mutational Escape and Sensitivity of the Omicron Variant.
 PMID: 35216287       2022       International journal of molecular sciences
Result: According to the recent study, the Omicron variant can escape the neutralization of many monoclonal antibodies, where the K417N, Q493R, and E484A Omicron mutations affect the recognition of class 1 and 2 antibodies targeting the ACE2 binding epitope.
Result: For VHH E binding, the large binding affinity loss resulted from E484A, Q493R, G496S, and N501Y mutations (Figure 7C,D).
Result: Hence, multiple Omicron RBD mutations (such as Q493R, G496S, Q498R, N501Y, Y505H) may have a measurable effect on allosteric couplings i


  Spike Gene Evolution and Immune Escape Mutations in Patients with Mild or Moderate Forms of COVID-19 and Treated with Monoclonal Antibodies Therapies.
 PMID: 35215820       2022       Viruses
Abstract: Four out of the 13 patients acquired a mutation during follow-up; two mutations (G1204E and E406G) appeared as a mixture without clinical impact, while the Q493R mutation emerged in two patients (one receiving bamlanivimab and one receiving bamlanivimab/etesevimab) with fatal outcomes.
Introduction: Some cases of Q493R mutations following bamlanivimab/etesevimab administration were also reported in the literature and are associated with a reduced viral clearance and, in some patients, with fatal outcome.
Result: All the patients recovered from COVID-19, except the two patients with the Q493R-acquired mutations.

Browser Board

 Co-occurred Entities




   Filtrator